Business Wire

NTT Com Launches Renewed SkyWay SDK for More Versatile Development of Online Communication Services

Share

NTT Communications Corporation (NTT Com), the ICT solutions and international communications business within the NTT group, announced today the immediate launch of the renewed SkyWay software development kit (SDK). The new SkyWay SDK makes it easier than ever to implement real-time voice, video and data communication for applications and websites.

People interested planning or developing online communication services may apply to attend a free webinar in person (50 people) or online (100 people) to learn about the renewed SkyWay SDK at NTT Communications' Tokyo headquarters from 3:00pm (JST) on February 23.

Simple to use and supported with extensive documentation, SkyWay does not require special technical skills or knowledge of voice/video communication or constructing servers, and can be used for a wide range of applications, such as online lessons, IoT and robots. To date, SkyWay has been deployed for the development of more than 20,000 services.

SkyWay is suitable for diverse call formats including voice and video, one-to-one and group calls, and video communication while sharing screens. It also is a multiplatform SDK for developing communication services suited to specific industries and business categories. SkyWay assures high-quality real-time communication, as evidenced by its service uptime rate of 99.96% in fiscal 2021. It also achieves high-quality overseas calls by setting up servers to relay communications to/from Asia, North America and Europe.1 What's more, SkyWay may be used at no charge for service verification and development until the users service is actually launched. Furthermore, fees are adjusted to the scale of service and billing is implemented on a pay-as-you-go billing basis.

Due to the COVID-19 pandemic, online communication has rapidly diversified and now commonly includes events involving dozens of people as well as communication robots. In response, NTT Com decided to upgrade SkyWay's architecture and release it as a new service with enhanced functions for increased versatility, including:

  • More simultaneous callers (expanded from 20 to 100 max.)
  • Terminal load reduction according to end-user environment (simulcasting2 and API for flexible media transmission/reception, such as only specific video/audio)
  • Authentication and authorization for controlling transmission of video/audio to each end user

The following are two examples of SkyWay's expanded functionality.

1. Virtual office
SkyWay can be used to create a system for an office-wide presentation reaching up to 100 people, with simulcasting allowing people to receive audio/video suitably adjusted to each user, such as low-resolution video to reduce system and battery load for mobile devices or terminals with low processing power. Also, participation can be controlled for private conferences.

2. Remote work support
SkyWay also can be used to create a system that allows a supervisor to remotely instruct multiple people at a worksite, using video for detailed directions and only audio if simple verbal directions are sufficient. Selective use of video and/or audio enables the system to reach many people with minimum load.

Service applications will be accepted from January 31. For details, please visit the website or contact a NTT Com sales representative, and for service rates, please see here. (Partially in Japanese only)

Looking ahead, NTT Com expects to further upgrade SkyWay by expanding the scale of voice and video calls, enhancing data communications for synchronization of more people, and supporting gaming platforms for live streaming and the metaverse. In addition, voice and video call experiences will be improved. Also, new SkyWay functions for measuring quality and analyzing problems will increasingly upgrade video and voice in diverse environments. Going forward, NTT Com will continue to develop SkyWay-related business to support the further evolution of real-time communication and its easy implementation by nonexperts in a world where people communicate meaningfully through the power of digital technology.

For more information about SkyWay, please visit here.

1 Technology that enables a terminal to select the most appropriate relay device in order to minimize delay between terminals (granted patent No. 6254620).
2 Technology for transmitting the same video to different terminals using different bitrates, such as low-resolution to mobile devices with limited processing power and bandwidth and high-resolution to PCs.

About NTT Communications
NTT Communications solves global technology challenges by helping enterprises utilize managed IT-infrastructure solutions to overcome complexity and risk in their IT environments. These solutions are backed by our worldwide infrastructure, including industry-leading, global tier-1 public and private networks reaching over 190 countries/regions, and more than 500,000m2 of the world's most advanced data-center facilities. As the core provider of the DOCOMO group's enterprise-business services and solutions, we create value by providing global-scale support for restructuring in industry and society, new workstyles and digital transformation in communities. Together with NTT Ltd., NTT Data and NTT DOCOMO, we are the NTT Group.
www.ntt.com | Twitter@NTT Com | Facebook@NTT Com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For more information
SkyWay Promotion Office
Platform Service Division
NTT Communications Corporation
E-mail: skyway@ntt.com 

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 20:30:00 EEST | Press release

Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were featured in two oral sessions (Investigational immunotherapy; Abstract #1522MO and Developmental therapeutics; Abstract #916O, respectively) at the European Society of Medical Oncology (ESMO) Congress 2025. “The proof-of-concept data highlight the potential of INCA33890 and INCB161734 to address significant medical needs in patients with advanced solid tumors, including MSS colorectal cancer and PDAC,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These results, including the favorable safety profiles as monotherapies, support continued clinical development. We look forward to explori

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release

Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye